期刊文献+

改良2-^(△△CT)法分析RNASET2基因在卵巢癌卡铂耐药中的表达 被引量:1

Analysis of RNASET2 Expression in Carboplatin-resistant Human Ovarian Carcinoma Cells Using A Modified 2^(-△△CT) Method in Real-time PCR
下载PDF
导出
摘要 目的:建立改良的相对定量2^(-△△CT)法并应用其分析RNASET2基因在卵巢癌卡铂耐药细胞系中的差异表达。方法:分别提取卵巢癌卡铂耐药SKOV3细胞系与其亲本SKOV3细胞系的总RNA,将等量的mRNA逆转录为cDNA,应用实时荧光定量PCR(real-time RT-PCR)技术检测核糖核酸酶T2(RNASET2)基因在卵巢癌卡铂耐药中的差异表达,参照2^(-△△CT)公式的推导步骤,对其改良演化出一个新的公式即改良2^(-△△CT)公式。以绝对定量法为对照,应用该公式分析real-time RT-PCR技术检测结果并比较两种方法的差异。结果:改良2^(-△△CT)公式与绝对定量法分析实验结果差异无统计学意义(P>0.05)。卵巢癌卡铂耐药SKOV3细胞系RNASET2基因的表达相对于卵巢癌非耐药SKOV3细胞系的表达降低。结论:改良2^(-△△CT)公式分析real-time RT-PCR反应数据是一种简便可行的相对定量方法,RNASET2表达下调与卵巢癌卡铂耐药相关。 Objective: To develop a modification of the 2^-△△CT method for relative quantification of gene expression and the differential expression of RNASET2 mRNA in earboplatin-resistant SKOV3 human ovarian eareinoma cell line. Methods: The total RNA were extracted from carboplatin-resistant SKOV3 cells and its parental cells, and cDNAs were prepared by reverse transcription (RT) with equal quantity mRNA derivied from these two kinds of cell respectively, and then the differential expressions of RNASET2 were determined by real-time PCR. A new 2^-△△CT formula for relative quantification in real-time PCR, called as a modified 2^-△△CT method,was derived from the deductive procedure of 2^-△△CT formula, and PCR data analysis of differential expressions of RNASET2 mRNA was carried out using this modified 2^-△△CT method, comparing with the absolute quantitative method with double standard curves. Results: Our findings showed that no significant difference was found in PCR data analysis with the two methods (P 〉 0.05) , and that the decreased expression of RNASET2 gene was found in carboplatin-resistant SKOV3 cells but not in SKOV3 eells. Conclusion: This modified 2^-△△CT method is a convenient way to analyze the relative changes in gene expression from real-time quantitative PCR experiments, and also provides a manageable method for examining large quantities of samples ; A further study will be needed to determine whether the downregtdation of RNASET2 expression may be related to drug resistance of human ovarian carcinoma.
出处 《肿瘤预防与治疗》 2009年第3期242-245,349,共5页 Journal of Cancer Control And Treatment
基金 广西壮族自治区卫生厅重点科研 课题基金资助 合同编号:重200865
关键词 卵巢癌 耐药 REAL-TIME PCR RNASET2 2^-△△CT法 Ovarian Carcinoma Resistance Real-time PCR RNASET2 2^-△△CT Method
  • 相关文献

参考文献8

  • 1Joseph A. Whelan, Nick B. Russell, Michael A. Whelan. A method for the absolute quantification of cDNA using real-time PCR [ J ]. Journal of Immunological Methods, 2003,278 : 261- 269.
  • 2Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T))Method[J]. Methods, 2001, 25(4): 402-408.
  • 3Watanabe Y, Ueda H, Etoh T, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinumbased chemotherapy in epithelial ovarian cancer [ J ]. Antieaneer Res, 2007, 27(3B) : 1449-1452.
  • 4栾英姿,李力,黎丹戎,张玮,唐步坚.五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达[J].中华妇产科杂志,2004,39(6):403-407. 被引量:21
  • 5Pfaffl M W. A new mathematical model for relative quantification in real-time RT-PCR [ J ]. Nucleic Acids Research, 2001,29 (900) :2002 - 2007.
  • 6Campomcnosi P, Salis S, Lindqvist C, et al. Characterization of RNASET2, the first human member of the Rh/T2/S family of glycoproteins[ J ]. Arch Biochem Biophys, 2006, 449 ( 1 - 2 ) : 17- 26.
  • 7Acquati F, Possati L, Ferrante L, et al. Tumor and metastasis suppression by the human RNASET2 gene[ J]. Adv Cancer Res, 1997,71:27-92.
  • 8Monti L, Rodolfo M,Lo Russo G,et al. RNASET2 as a tumor antagonizing gene in a melanoma cancer model [ J ]. Oncol Res, 2008, 17(2) :69-74.

二级参考文献15

  • 1Webb BL, Lindsay MA, Seybold J, et al. Identification of the protein kinase C isoenzymes in human lung and airways ooth muscle at the protein and mRNA level.Biochem Pharmacol, 1997,54:199-205.
  • 2Withoff S, van der Zee AG, de Jong S, et al. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.Br J Cancer,1999,79:748-753.
  • 3Fajac A, Da Silva J, Ahomadegbe JC, et al. Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line.Int J Cancer,1996,68:67-74.
  • 4Satoh T, Nishida M, Tsunoda H, et al. Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors.Eur J Obstet Gynecol Reprod Biol, 2001,96:202-208.
  • 5Hill BT, Moran E, Etievant C, et al. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1.Anticancer Drugs,2000,
  • 6Cvitkovic E. Ongoing and unsaid on oxaliplatin: the hope.Br J Cancer,1998,77 Suppl 4:8-11.
  • 7Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.Cancer Res, 1996,56:556-562.
  • 8Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.Cancer Res, 2001,61:1862-1868.
  • 9Cui W, Yazlovitskaya EM, Mayo MS, et al. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal--regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines.Mol Carcinog,2000, 29:219-228.
  • 10Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, et al. Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.Am J Pathol,2001,158:1335-1344.

共引文献20

同被引文献6

  • 1Balch C,Huang TH,Brown R,et al.The epigenetics of ovarian cancer drug resistance and resensitization[J].Am J Obstet Gynecol,2004,191(5):1552-1572.
  • 2Singal R,Ginder GD.DNA methy lation[J].Blood,1999,93(12):4059-4070.
  • 3Lund AH,Lohuizen M.Epigenetics and cancer[J].Genes Dev,2004,18(19):2315-2335.
  • 4Staub J,Chien J,Pan Y,et al.Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance[J].Oncogene,2007,26(34):4969-4978.
  • 5Watanabe Y,Ueda H,Etoh T,et al.A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res,2007,27(3):1449-524.
  • 6Strathdee G,Vass JK,Oien KA,et al.Demethylation of the MCJ gene in stage Ⅲ /Ⅳ epithelial ovarian cancer and response to chemotherapy[J].Gynecol Oncol,2005,97(3):898-903.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部